Stress Mechanisms and Metabolic Complications

Abstract

Stress can be defined as a state of threatened homeostasis or disharmony. An intricate repertoire of physiologic and behavioral responses is mobilized under stressful situations forming the adaptive stress response that aims to reestablish the challenged body equilibrium. The hypothalamic-pituitary-adrenal axis and the central and peripheral components of the autonomic nervous system constitute the two main pillars that subserve the vital functions of the stress system. Chronic stress represents a prolonged threat to homeostasis that can progressively lead to a deleterious overload with various complications caused by both the persistent stressor and the detrimental prolongation of the adaptive response. Recent data indicate that chronic stress is associated to derangement of metabolic homeostasis that contributes to the clinical presentation of visceral obesity, type 2 diabetes, atherosclerosis and metabolic syndrome. Notably, indices of stress in the modern western societies correlate with the increasing incidence of both obesity and the metabolic syndrome which have reached epidemic proportions over the past decades. The pathogenetic mechanisms that accommodate these correlations implicate primarily the chronic hyperactivation of the HPA axis under prolonged stress, which favors accumulation of visceral fat, and vice versa; obesity constitutes a chronic stressful state that may cause HPA axis dysfunction. In addition, obesity is being now recognized as a systemic low grade inflammatory state that contributes to the derangement of the metabolic equilibrium, implicating the adipocyte secretion of adipokines to the pathogenesis of several components of the metabolic syndrome. Understanding the mechanisms that mediate the documented reciprocal relationships between stress and metabolic homeostasis will hopefully provide novel insights to the pathophysiology of obesity, type 2 diabetes, and their cardiometabolic complications, and will help the quest for more specific and effective therapeutic interventions.

Stress - glucocorticoids - cytokines - obesity - metabolic syndrome - inflammation - depression

References

• 1 Chrousos GP, Gold PW. The concepts of stress system disorders: Overview of behavioral and physical homeostasis.  JAMA. 1992;  267 1244-1252
• 2 Tsigos C, Kyrou I, Chrousos GP. Stress, endocrine manifestations, and diseases. In: Cooper CL. (ed.) Handbook of Stress, Medicine, and Health. 2nd Edition Boca Raton FL: CRC Press 2005: 101-131
• 3 Calogero AE, Gallucci WT, Gold PW. et al . Multiple regulatory feedback loops on hypothalamic CRH secretion. Potential clinical implications.  J Clin Invest. 1988;  82 767-774
• 4 Vale W, Spiess J, Rivier C. et al . Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.  Science. 1981;  213 1394-1397
• 5 Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family.  Ann N Y Acad Sci.. 1999;  885 312-328
• 6 Grammatopoulos DK, Chrousos GP. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists.  Trends Endocrinol Metab. 2002;  13 436-444
• 7 Tsigos C, Chrousos GP. Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders.  Endocrinol Metab Clin North Am. 1994;  23 451-466
• 8 Rivier C, Rivier J, Mormede P. et al . Studies on the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat.  Endocrinology. 1984;  115 882-886
• 9 Korbonits M, Kaltsas G, Perry LA. et al . The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.  J Clin Endocrinol Metab. 1999;  84 2489-2495
• 10 Heilig M, Widerlov E. Neurobiology and clinical aspects of neuropeptide Y.  Crit Rev Neurobiol. 1995;  9 115-136
• 11 Jessop DS, Chowdrey HS, Larsen PJ. et al . Substance P: multifunctional peptide in the hypothalamo-pituitary system?.  J Endocrinol. 1992;  132 331-337
• 12 Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress.  J Psychosom Res. 2002;  53 865-871
• 13 Horrocks PM, Jones AF, Ratcliffe WA. et al . Patterns of ACTH and cortisol pulsatility over twenty-four hours in normal males and females.  Clin Endocrinol (Oxf). 1990;  32 127-134
• 14 Chrousos GP. Ultradian, circadian, and stress-related hypothalamic-pituitary-adrenal axis activity - a dynamic digital-to-analog modulation.  Endocrinology. 1998;  139 437-440
• 15 Pratt WB. Glucocorticoid receptor structure and the initial events in signal transduction.  Prog Clin Bilo Res. 1990;  322 119-320
• 16 Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids.  Endocr Rev. 1996;  17 245-261
• 17 Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action.  Curr Pharm Des. 2004;  10 2807-2816
• 18 Rozanski A, Blumenthal JA, Davidson KW. et al . The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology.  J Am Coll Cardiol. 2005;  45 637-651
• 19 Roth RH, Tam SY, Ida Y. et al . Stress and the mesocorticolimbic dopamine systems.  Ann N Y Acad Sci. 1988;  537 138-147
• 20 Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture.  Ann N Y Acad Sci. 1998;  851 311-335
• 21 Fuchs E, Flugge G, Czeh B. Remodeling of neuronal networks by stress.  Front Biosci. 2006;  11 2746-2758
• 22 Richard D, Lin Q, Timofeeva E. The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance.  Eur J Pharmacol. 2002;  440 189-197
• 23 Egawa M, Yoshimatsu H, Bray GA. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats.  Am J Physiol. 1991;  260 328-334
• 24 Heiman ML, Ahima RS, Craft LS. et al . Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress.  Endocrinology. 1997;  138 3859-3863
• 25 Bornstein S, Uhlmann K, Haidan A. et al . Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: leptin inhibits cortisol release directly.  Diabetes. 1997;  46 1235-1238
• 26 Kalra SP, Dube MG, Pu S. et al . Interacting appetite-regulating pathways in the hypothalamic regulation of body weight.  Endocr Rev. 1999;  20 68-100
• 27 Cavagnini F, Croci M, Putignano P. et al . Glucocorticoids and neuroendocrine function.  Int J Obesity. 2000;  24 S77-S79
• 28 Kyrou I, Valsamakis G, Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.  Ann N Y Acad Sci. 2006;  1083 270-305
• 29 Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes.  Int J Obesity. 2000;  24 S50-S55
• 30 Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications.  Ann N Y Acad Sci. 2006;  1083 77-110
• 31 MacAdams MR, White RH, Chipps BE. Reduction in serum testosterone levels during chronic glucocorticoid therapy.  Ann Intern Med. 1986;  140 648-651
• 32 Rivier C, Rivier J, Vale W. Stress-induced inhibition of reproductive function: Role of endogenous corticotropin releasing factor.  Science. 1986;  231 607-609
• 33 Tsigos C, Papanicolaou DA, Kyrou I. et al . Dose-dependent effects of recombinant human interleukin-6 on the pituitary-testicular axis.  J Interferon Cytokine Res. 1999;  19 1271-1276
• 34 Burguera B, Muruais C, Penalva A. et al . Dual and selective actions of glucocorticoids upon basal and stimulated growth hormone release in man.  Neuroendocrinology. 1990;  51 51-58
• 35 Benker G, Raida M, Olbricht T. et al . TSH secretion in Cushing's syndrome: Relation to glucocorticoid excess, diabetes, goiter, and the “the sick euthyroid syndrome”.  Clin Endocrin. 1990;  133 779-786
• 36 Tsigos C, Papanicolaou DA, Defensor R. et al . Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure.  Neuroendocrinology. 1997;  66 54-62
• 37 Torpy DJ, Tsigos C, Lotsikas AJ. et al . Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humans.  Metabolism. 1998;  47 1289-1293
• 38 Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation.  New Eng J Med. 1995;  332 1351-1362
• 39 Kyrou I, Tsigos C. Hypothalamic-pituitary-adrenal axis, cytokines and metabolic syndrome.  Obesity Metab. 2006;  2 116-126
• 40 Elenkov IJ, Chrousos GP. Stress hormones, pro-inflammatory and anti-inflammatory cytokines, and autoimmunity.  Ann N Y Acad Sci. 2002;  966 290-303
• 41 Black PH. The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X.  Brain Behav Immun. 2003;  17 350-364
• 42 Selye H. A syndrome produced by diverse nocuous agents.  Nature. 1936;  138 32
• 43 Selye H. The general adaptation syndrome and the diseases of adaptation.  J Clin Endocrinol. 1946;  6 117-230
• 44 Charmandari E, Tsigos C, Chrousos GP. Endocrinology of the stress response.  Annu Rev Physiol.. 2005;  67 259-284
• 45 Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities?.  Obes Rev. 2001;  2 73-86
• 46 Hainer V, Kunesova M, Parizkova J. et al . Serum cortisol and sex hormone binding globulin (SHBG) levels, body fat distribution and the role of genetic factors in obese females.  Sb Lek. 2002;  103 471-475
• 47 Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity.  Int J Obes Relat Metab Disord. 2000;  24 S80-S85
• 48 Rosmond R, Holm G, Bjorntorp P. Food-induced cortisol secretion in relation to anthropometric, metabolic and haemodynamic variables in men.  Int J Obes Relat Metab Disord. 2000;  24 416-422
• 49 Chandola T, Brunner E, Marmot M. Chronic stress at work and the metabolic syndrome: prospective study.  BMJ. 2006;  332 521-525
• 50 Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ.  Diabetes. 2006;  55 1537-1545
• 51 Snijder MB, Zimmet PZ, Visser M. et al . Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study.  Int J Obes Relat Metab Disord. 2004;  28 402-409
• 52 Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition.  Lancet. 2005;  366 1059-1062
• 53 Schaffler A, Muller-Ladner U, Scholmerich J. et al . Role of adipose tissue as an inflammatory organ in human diseases.  Endocr Rev. 2006;  27 449-467
• 54 Tsigos C, Kyrou I, Chala E. et al . Circulating tumor necrosis factor a levels are higher in abdominal than peripheral obesity.  Metabolism. 1999;  48 1332-1335
• 55 Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue.  Br J Nutr. 2004;  92 347-355
• 56 Tsigos C, Papanicolaou DA, Kyrou I. et al . Dose-dependent effects of recombinant human interleukin-6 on glucose regulation.  J Clin Endocrinol Metab. 1997;  82 4167-4170
• 57 Dallman MF, Pecoraro N, Akana SF. et al . Chronic stress and obesity: a new view of “comfort food”.  Proc Natl Acad Sci USA. 2003;  100 11696-11701
• 58 Anderson RJ, Freedland KE, Clouse RE. et al . The prevalence of comorbid depression in adults with diabetes. A meta-analysis.  Diabetes Care. 2001;  24 1069-1078
• 59 Kawakami N, Takatsuka N, Shimizu H. et al . Depressive symptoms and occurrence of type 2 diabetes among Japanese men.  Diabetes Care. 1999;  22 1071-1076
• 60 Everson-Rose SA, Meyer PM, Powell LH. et al . Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife.  Diabetes Care. 2004;  27 2856-2862
• 61 Bjorntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus.  Diabetic Med. 1999;  16 373-383
• 62 Rubin RR, Peyrot M. Was Willis right?. Thoughts on the interaction of depression and diabetes.  Diabetes Metab Res Rev. 2002;  18 173-175
• 63 Surwit RS, van Tilburg MAL, Zucker N. et al . Stress management improves long-term glycemic control in type 2 diabetes.  Diabetes Care. 2002;  25 30-34
• 64 Adriaanse MC, Dekker JM, Nijpels G. et al . Associations between depressive symptoms and insulin resistance: The Hoorn Study.  Diabetologia. 2006;  49 2874-2877
• 65 Barzilay JI, Abraham L, Heckbert SR. et al . The relation of markers of inflammation to the development of glucose disorders in the elderly. The Cardiovascular Health Study.  Diabetes. 2001;  50 2384-2389
• 66 Schmidt MI, Duncan BB, Sharrett AR. et al . For the ARIC Investigators. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study.  Lancet. 1999;  353 1649-1652

Correspondence